Search
Tenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigationalTenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsDeflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. Duchenne Muscular Dyst...
Synonyms: 11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE, 5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersTasisulam
go.drugbank.com/drugs/DB11941InvestigationalTasisulam has been used in trials studying the treatment and basic science of Melanoma, Lymphoma, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalDelafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP3A InducersLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalLemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (Doptelet), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation, thereby decreasing the need for blood transfusions. Patient...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various bio...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates